The duration of postoperative acute kidney injury is an additional parameter predicting long-term survival in diabetic veterans  by Coca, Steven G. et al.
The duration of postoperative acute kidney injury
is an additional parameter predicting long-term
survival in diabetic veterans
Steven G. Coca1,2, Joseph T. King Jr3,4, Ronnie A. Rosenthal3,5, Melissa F. Perkal3,5 and Chirag R. Parikh1,2
1Clinical Epidemiology Research Center, Veterans Affairs Medical Center, West Haven, Connecticut, USA; 2Department of Medicine, Yale
University School of Medicine, New Haven, Connecticut, USA; 3Surgical Section, VA Connecticut Healthcare System, West Haven,
Connecticut, USA; 4Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA and 5Department of
Surgery, Yale University School of Medicine, New Haven, Connecticut, USA
Acute kidney injury (AKI) is primarily defined and staged
according to the magnitude of the rise in serum creatinine.
Here we sought to determine if the duration of AKI adds
additional prognostic information above that from the
magnitude of injury alone. We prospectively studied 35,302
diabetic patients from 123 Veterans Affairs Medical Centers
undergoing their first noncardiac surgery. The main outcome
was long-term mortality in those who survived the index
hospitalization. AKI was stratified by magnitude according
to AKI Network stages and by the duration (short (less than
2 days), medium (3–6 days) or long (7 days or more)). Overall,
17.8% of patients experienced at least stage 1 AKI or greater
following surgery. Both the magnitude and duration of AKI
were significantly associated with long-term survival in a
dose-dependent manner. Within each stage, longer duration
of AKI was significantly associated with a graded higher rate
of mortality. However, within each of the duration categories,
the stage was not associated with mortality. When
considered separately in multivariate analyses, both a higher
stage and duration were independently associated with
increased risk of long-term mortality. Hence, the duration
of AKI adds additional information to predict long-term
mortality.
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Acute kidney injury (AKI) is a common and complex
disorder, and frequently occurs in hospitalized patients.1
Although AKI has been conceptualized by abrupt elevations
in serum creatinine, for decades there has been a lack of a
consensus definition. Recently, the Acute Dialysis Quality
Initiative (ADQI) and the Acute Kidney Injury Network
(AKIN) developed new classification systems for AKI. The
ADQI proposed the Risk, Injury, Failure, Loss of Kidney
Function, and End-Stage Kidney Disease (RIFLE) classifica-
tion2 and subsequently the AKIN group made a slight
modification to the RIFLE classification system.3 Implicit in
both these classification systems is a dose–response relation-
ship between severity of AKI stage and outcome.4–9 The
RIFLE and AKIN definitions of AKI primarily involve a
magnitude component and take into account the degree of
elevation of serum creatinine. The AKIN and RIFLE systems
do not take into account etiology, duration of serum
creatinine elevation, or recovery into its assessment of AKI.
In clinical practice, many data elements, in addition to
the absolute elevation in serum creatinine, are considered in
assessing the severity and prognosis after AKI. An important
parameter that is often accounted for by clinicians is the
duration of AKI. Fundamentally, the duration of AKI, along
with examination of the urine sediment,10 helps to diff-
erentiate between ‘prerenal AKI’ and ‘intrinsic AKI’ or acute
tubular necrosis. In fact, it can be argued that the duration of
the elevation of serum creatinine is the most important factor
when trying to differentiate between prerenal and intrinsic
AKI. Significant azotemia can be witnessed in the setting of
severe prerenal dysfunction, and the urinary sediment is
not always completely accurate for distinguishing between
these two entities.10 However, brisk recovery, thereby a short
duration of AKI, suggests that the elevation of serum
creatinine was probably not due to intrinsic AKI. Intrinsic
AKI involves tubular cell injury and the process of repair,
which involves dedifferentiation and redifferentiation, and
takes more than 24–48 h.11,12
The objective of this project was to explore the association
between duration of AKI and long-term mortality and to
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examine whether duration of AKI offered any additional
prognostic information over the magnitude of elevation in
serum creatinine. We chose to investigate these relationships
in a population of postoperative AKI, as the timing of the
insult is known. Thus, the duration of AKI is less confounded
by repeated clinical or subclinical insults that could occur in a
typical hospitalized or critically ill population.
RESULTS
Patient characteristics
Among the 35,302 veterans who underwent noncardiac
surgery between 2000 and 2004 and met our inclusion
criteria, the median length of hospital admission was 6 days
(range 0–314 days). Patients surviving hospitalization for
noncardiac surgery were divided into three categories of
AKI by AKIN stage (magnitude) and by three categories of
duration of AKI. A total of 6257 (17.8%) patients had some
degree of AKI by AKIN criteria (stage 1: 14.5%, stage 2: 2.2%,
stage 3: 1.1%); 4205 (11.9%) experienced short duration of
AKI (p2 days), 1379 (3.9%) experienced medium duration
(3–6 days), and 673 (1.9%) experienced long duration (X7
days) of AKI. Baseline characteristics by strata of AKIN and
AKI duration are shown in Table 1 and incidence of AKI by
AKIN stage and duration is shown in Table 2.
Long-term survival
Among the 35,302 survivors of hospitalization, 14,582 deaths
occurred during 123,118 patient-years of follow-up (mortal-
ity rate 11.8 per 100 person-years). Overall, the median
length of follow-up for the entire cohort was 3.8 years
(mean 3.7 years, range 0–7.9 years). The median length of
survival decreased with both magnitude and duration of AKI
(Table 1). Long-term survival was significantly different
by both AKIN stage (Figure 1a; log-rank test Po0.001) and
by duration of AKI (Figure 1b; log-rank test Po0.001).
Adjusted hazard ratios for each AKI category as defined in
separate models by magnitude and duration are summarized
in Table 3. Both AKIN stage and AKI duration were indepen-
dently associated with long-term mortality. However, because
of significant colinearity between magnitude and duration of
AKI (r¼ 0.87), we were unable to include both variables in
the same Cox Proportional Hazards model. The relationship
between duration of AKI and long-term survival was not
modified by preexisting CKD (P¼ 0.92 for interaction).
To better understand the prognostic role of duration of
AKI, we examined subgroups of AKI, first by each stage of
AKIN stratified by duration and then by AKI duration
stratified by AKIN. We plotted the magnitude and duration
of AKI on a two-way graph with mortality rates (Figure 2).
As the duration of AKI increased within each strata of AKI
severity as defined by the AKIN criteria (magnitude), survival
after hospitalization decreased. However, survival did not
significantly change within each strata of AKI as classified
by duration (Figure 2, Table 4). Notably, the mortality rates
were greater for those with the lowest AKIN stage and
with medium (3–6 days) or long (X7 days) duration of AKI
(21.5 and 29.3 deaths per 100 person-years, respectively)
than for those with the most severe AKIN stage but short
(p2 days) duration of AKI (12.8 deaths per 100 person-
years). These relationships were confirmed when we exam-
ined the stratified survival plots. Patients with increasing
duration of AKI had significantly worse survival in every
stage of AKIN (log-rank test Po0.001 for all three strata;
Figure 3). In contrast, when patients were stratified by the
duration of AKI, the magnitude of creatinine increase as
classified by AKIN was not significantly associated with
survival in those with short and medium length of AKI
(P-values for log-rank test 40.05; Figure 4). When patients
who required acute renal replacement (n¼ 132) postopera-
tively were examined separately from the rest of the cohort,
they had the highest risk of death (adjusted hazard ratio 2.65,
95% confidence interval 2.0–3.52).
Supplementary analyses: AKI recovery and long-term
survival
We examined the relationship between duration of AKI,
recovery of AKI, and survival in those with AKI who hadX7
postoperative serum creatinine values. A total of 3207
patients who experienced AKI had X7 serum creatinine
values, of whom 1570 (50%) had short, 984 (31%) had
medium, and 653 (20%) had long duration of AKI. Among
these patients, 2269 (71%) recovered to within 0.2mg/dl of
baseline by the time of discharge. Duration of AKI was
associated with recovery (proportion of those with short,
medium, long AKI who recovered 88, 72, 28%, respectively;
Po0.001). Long-term survival was significantly better in
those who recovered vs those who did not (median survival
1088 days vs 897 days, respectively; log-rank test Po0.001).
When stratified by recovery status and three lengths of
duration, the duration of AKI was still significantly associated
with long-term survival in both those who had nonrecovery
and those who recovered (log-rank test P¼ 0.006 and
Po0.001, respectively).
DISCUSSION
In this large, multicenter US Veterans Affairs-based surgical
database, we demonstrated that the duration of AKI is
independently associated with long-term mortality. This is
the largest study to date that demonstrates the prognostic
importance of duration of AKI. Furthermore, when we
controlled for magnitude of rise in serum creatinine, the
duration of AKI within each strata of AKIN stage was
associated with long-term survival in a clear dose-dependent
manner. In contrast, the AKIN stages of AKI provided
little additional prognostic information once duration of AKI
was controlled. Most impressive was the fact that the
mortality rate for those with severe AKI (stage 3 AKIN)
and short duration (p2 days) was B50% lower than for
those with the most mild stage of AKI (stage 1 AKIN) and
with medium (3–6 days) or long (X7 days) duration of AKI.
These findings, although potentially intuitive, are novel in the
AKI literature and demonstrate the limitations of the current
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AKI classification systems. Only a few smaller studies have
stratified survival by whether AKI recovered by the time
of hospital discharge13,14 or within 3 days of manifestation of
AKI;15 however, these analyses were not as detailed as ours,
nor were the interactions between various degrees of
AKI magnitude and duration and recovery examined as
thoroughly as in this study. Herein, we demonstrated that
duration of AKI still provided prognostic information even in
patients with AKI who recovered kidney function back to
baseline by the time of hospital discharge.
Most, if not all, previous publications on long-term
prognosis after AKI have focused solely on characterizing the
severity of AKI by the magnitude in rise of serum creatinine.
Thus, it is highly likely that there was imperfect characteriza-
tion of risk associated with AKI in all previous studies
solely using the existing magnitude-based criteria for AKI.
Table 1 | Patient baseline characteristics and the AKIN staging system and AKI duration
AKI
AKIN stage AKI duration
No AKI Stage 1 Stage 2 Stage 3
Short
(p2 days)
Medium
(3–6 days)
Long
(X7 days)
Overall 29,045 (82.3) 5109 (14.5) 760 (2.2) 388 (1.1) P-value 4205 (11.9) 1379 (3.9) 673 (1.9) P-value
Demographics
Age (years) 66±10 67±10 66±10 66±11 o0.001 67±10 68±10 68±10 o0.001
Male 97 98 98 96 0.08 98 99 98 o0.001
White 67 65 65 63 0.005 64 67 67 0.12
Comorbidities
COPD 15 18 18 22 o0.001 17 20 23 o0.001
Diabetes 41 50 46 50 o0.001 47 53 55 o0.001
Ventilator dependent 1 2 2 7 o0.001 1.2 2.5 6.4 o0.001
Smoker 28 26 25 34 0.08 26 24 29 0.008
Preoperative infection 22 25 24 34 o0.001 23 30 34 o0.001
Functional dependency 17 21 22 23 o0.001 19 24 27 o0.001
Alcohol use 42 drinks per day 6 6 8 7 0.56 6 6 8 0.59
Weight loss 40% in the
last 6 months
4 5 8 7 o0.001 5 7 10 o0.001
Surgery characteristics
OR time (min) 143±102 166±122 174±120 176±134 o0.001 163±119 167±120 197±146 o0.001
General anesthesia 79 82 86 89 o0.001 82 84 90 o0.001
ASA class 4/5 17 25 25 33 o0.001 21 30 42 o0.001
Emergency case 10 12 13 20 o0.001 11 15 21 o0.001
Specialty of surgeon N/A N/A
General surgery 32 34 38 36 — 34 36 37 —
Neurosurgery 5 4 4 3 — 4 4 2 —
Orthopedic surgery 18 18 18 18 — 20 15 12 —
Thoracic surgery 4 7 8 8 — 6 7 8 —
Urologic surgery 12 12 11 7 — 12 12 7 —
Vascular surgery 24 21 17 26 — 20 22 29 —
Other 6 4 4 4 — 4 4 5 —
Preoperative laboratory values
Hematocrit (%) 38±6 36±6 36±6 35±6 o0.001 37±6 35±6 34±6 o0.001
White blood cells (1000/ml/mm3) 8.9±4.4 9.1±5.4 9.0±5.0 10.0±5.2 o0.001 9.0±5.6 9.4±4.7 9.9±5.1 o0.001
Serum albumin (g/dl) 3.5±0.7 3.3±0.8 3.3±0.8 3.2±0.8 o0.001 3.4±0.7 3.2±0.8 3.0±0.8 o0.001
Serum creatinine (mg/dl) 1.2±0.5 1.3±0.6 1.1±0.5 1.3±0.8 o0.001 1.2±0.5 1.4±0.7 1.5±0.8 o0.001
GFR o0.001 o0.001
X60ml/min per 1.73m2 73 58 74 65 — 65 52 47 —
30–59ml/min per 1.73m2 25 36 24 24 — 31 39 39 —
o30ml/min per 1.73m2 3 6 1 10 — 4 8 14 —
HbA1C (%) 8.0±2.0 7.9±2.0 7.9±2.0 7.9±2.2 0.78 7.9±2.0 7.9±2.0 7.8±2.0 0.25
Mean glucose, 24 h
postoperative (mg/dl)
184±61 196±68 199±70 189±67 o0.001 197±70 194±65 191±64 o0.001
Median survival (years) 3.8 3.3 3.0 2.4 o0.001 3.5 2.9 2.1 o0.001
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ASA, American Society of Anesthesiologists; COPD, chronic obstructive pulmonary disease; GFR,
glomerular filtration rate; HbA1C, hemoglobin A1C.
Values are percentages for categorical variables and mean±s.e. for continuous variables.
P-values represent results from Mantel–Hantzel w2-test for trend for categorical variables and represent results from analysis of variance for continuous variables.
N/A: P-values not calculated for the type of surgery.
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Our findings have important implications for the field of
AKI. The current consensus definition for AKI as proposed
by the AKIN group does not incorporate any duration
component into the definition. However, given the fact that
we found that the granularity of the risk associated with AKI
Table 2 | Incidence of AKI by AKIN stage (magnitude)
stratified by duration of AKI
AKI duration
AKIN stage
Short
(p2 days),
n (%)
Medium
(3–6 days),
n (%)
Long
(X7 days),
n (%)
1 3810 (74.6) 1050 (20.6) 249 (4.9)
2 294 (38.7) 266 (35.0) 200 (26.3)
3 101 (26.0) 63 (16.2) 224 (57.7)
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network.
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Figure 1 |Kaplan–Meier survival plots of acute kidney injury
(AKI) by magnitude and duration. (a) Survival among patients
by Acute Kidney Injury Network (AKIN) stages of AKI vs no
AKI. Increasing AKIN stage is associated with worse survival.
(b) Survival among patients by duration of AKI vs no AKI.
Increasing duration of AKI is associated with worse survival.
Table 3 | Adjusted hazard ratios for mortality after
hospitalization by AKI definitions
95% CI
HR Upper Lower
AKIN
Stage 1 1.24 1.17 1.31
Stage 2 1.64 1.43 1.88
Stage 3 1.96 1.63 2.37
Duration
Short (p2 days) 1.15 1.07 1.23
Medium (3–6 days) 1.50 1.36 1.66
Long (X7 days) 2.01 1.77 2.28
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ASA,
American Society of Anesthesiologists; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; HR, hazard ratio; GFR, glomerular filtration rate;
HbA1C, hemoglobin A1C.
Variables in final model for AKIN stage of AKI include the following: age, sex, race,
chronic insulin use, mean 24-h postoperative glucose (categorical), operative time,
ASA class 4/5, emergency surgery, baseline GFR, preoperative infection, functional
dependency, smoking status, weight loss 410% in the last 6 months, chronic
alcohol intake, COPD, preoperative albumin, hematocrit, white blood cell count, and
hemoglobin A1C.
Variables in final model for AKI duration include the same variables.
Referent groups are those without AKI.
45
40
35
30
25
20
15
10
5
0
1 2
3
 7 days
3–6 days
Du
ra
tio
n
 2 days
AKIN stage
M
or
ta
lit
y 
ra
te
 (p
er 
10
0 p
ers
on
-ye
ars
)
Figure 2 |Mortality rates by magnitude and duration of acute
kidney injury (AKI). No increase in mortality rate is seen by Acute
Kidney Injury Network (AKIN) stage within AKI as stratified by
duration. However, the mortality rate increased by duration within
AKI when stratified by AKIN stage. The mortality rate for those
with AKIN stage 1 and with long duration (X7 days) of AKI is more
than twofold higher than for those with AKIN stage 3 and short
duration (p2 days) of AKI.
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with regard to long-term mortality is increased by examining
not only the magnitude of rise in serum creatinine but also
the duration of the rise, future studies should use at least this
two-dimensional approach (magnitude and duration) to
analyze outcomes of AKI. Although the magnitude and
duration of AKI were highly associated with each other, the
addition of another dimension to classification of AKI should
be sought after and embraced. It is clear from clinical practice
and from our data that a patient who experiences a large
(for example, threefold) but brief increase in serum
creatinine is phenotypically very different from a patient
who experiences a sustained increase of 50%. The current
classification systems inappropriately assign higher risk to the
first patient because the change in creatinine is numerically
greater.
Classification of AKI by duration may discriminate
between patients with ‘prerenal’ or hemodynamic AKI that
does not result in any true injury to the renal tubular cells
and those with true intrinsic renal injury (that is, ‘acute
tubular necrosis’). In addition, the duration of AKI may be
a surrogate of the recovery potential of the injured kidney.
Table 4 | Incidence rate of death by AKI magnitude and
duration
Group
Number
of
subjects
Person-years
follow-up
Number
of
deaths
Mortality
rate (deaths
per 100
person-years)
All patients 35,302 123,118 14,582 11.8
No AKI 29,067 103,753 11,382 11.0
AKIN stage 1
Short (p2 days) 3642 12,748 1744 13.7
Medium (3–6 days) 1021 2975 641 21.5
Long (X7 days) 241 569 167 29.3
AKIN stage 2
Short (p2 days) 284 1001 126 12.6
Medium (3–6 days) 260 758 151 19.9
Long (X7 days) 188 422 145 34.3
AKIN stage 3
Short (p2 days) 97 328 42 12.8
Medium (3–6 days) 63 185 36 19.5
Long (X7 days) 217 386 169 43.8
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network.
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Figure 3 |Kaplan–Meier survival plots: Acute Kidney Injury Network (AKIN) stages stratified by duration. Survival among patients by
short (p2 days), medium (3–6 days), and long (X7 days) duration of acute kidney injury (AKI) with AKIN stages 1, 2, and 3 (panels a–c,
respectively). Patients with increasing duration of AKI had significantly worse survival in every stage of AKIN.
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Some patients may be able to regain proper functioning of
renal tubular cells more quickly because of younger age,16–18
more renal mass, or faster restoration of renal medullary
blood flow. In addition, the duration of AKI may be reflective
of the overall severity of illness of the patient, as those who
are more severely ill and have continued extrarenal organ
dysfunction will take longer to recover. In contrast, the
magnitude of serum creatinine increase depends on muscle
mass and volume status, and may not always be reflective of
true tubular injury or the extent of injury. First, there is no
doubt that patients with prerenal AKI may achieve a serum
creatinine concentration as high or even higher in some
cases than patients with acute tubular necrosis, particularly
in patients on agents that impair renal autoregulation (for
example, non-steroidal anti-inflammatory drugs, angiotensin
converting enzyme inhibitors).19–21 Second, the ability to
generate higher serum creatinine is not only dependent on a
reduction in the glomerular filtration rate but also dependent
on the production of creatinine from skeletal muscle. Thus,
in response to an insult of equal magnitude, a more robust
and muscular patient will achieve a greater increase in serum
creatinine than a frail, chronically ill patient. The robust and
muscular patient will be more likely to survive long term
than the frail patient.
Our study does have some limitations. First, the results
may lack generalizability. The population in this study was
comprised solely of diabetic veterans who underwent
noncardiac surgery, and was predominantly male. Whether
the same findings apply to nondiabetics in all clinical settings
and to females is unknown. Second, we did not have data on
urine output, which is a component of the AKIN definition.
It is possible that the results may have differed if urine output
was incorporated into the AKIN definition of AKI applied to
this cohort of patients. However, a recent study demonstrated
that serum creatinine determined the maximum AKIN stage
achieved for 95% of patients.6 Third, serum creatinine values
were obtained as a part of clinical practice. This may have
provided some ascertainment bias toward AKI and to the
evaluation of its severity. Fourth, similar to any observational
study, we may have residual confounding from known and
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Figure 4 |Kaplan–Meier survival plots: acute kidney injury (AKI) duration stratified by Acute Kidney Injury Network (AKIN)
stages. Survival among patients by AKIN stages 1, 2, and 3 with short (p2 days), medium (3–6 days), and long (X7 days) duration of AKI
(panels a–c, respectively). Once stratified by duration of AKI, minimal additional prognostic information is offered by magnitude of
creatinine rise.
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unknown variables, which may attenuate the relationship
between AKI duration and mortality. Finally, we did not have
any data from the time after discharge until the time of death.
Thus, we do not know the intermediate outcomes, effects of
treatment, and cause of death of patients in this cohort.
In conclusion, the duration of AKI is independently
associated with long-term mortality and may provide addi-
tional prognostic information than magnitude of serum
creatinine alone in patients who survive AKI after hospitaliza-
tion for noncardiac surgery. These data need to be validated in
other settings of AKI, and if found to be true, duration of
AKI should be incorporated into the consensus definitions of
AKI and used in clinical studies of AKI in the future.
MATERIALS AND METHODS
This study was conducted and reported according to the Stren-
gthening the Reporting of OBservational studies in Epidemiology
(STROBE) consensus statement.22
Data sources and patients
The Veterans Affairs (VA) National Surgical Quality Improvement
Program (NSQIP) was established in 1994 for continuous quality
improvement with noncardiac surgery in the United States. The
NSQIP is the first validated, comprehensive, national outcome-
based, and peer-controlled program for measuring and improving
the quality of noncardiac surgical care. Automated electronic
medical record data extraction and standardized manual data
collection by NSQIP surgical nurse reviewers provide extensive
preoperative, intraoperative, and postoperative data on patients
undergoing noncardiac operations at 123 VA medical centers.23 We
supplemented NSQIP data by merging with additional laboratory
data (for example, serum creatinine) obtained from the VA Decision
Support System at the Austin Information Technology Center in
Austin, Texas.
All diabetic veteran patients with both pre- and postoperative
serum creatinine values, yet without preoperative AKI or end stage
renal disease, who underwent noncardiac surgery between 1 October
2000 and 30 September 2004 were eligible for this study. We chose to
study only diabetic patients in order to enrich the incidence of AKI
in the cohort. We excluded 952 with metastatic cancer because of
short-life expectancy, and 2651 patients who died during their
hospital stay. If patients had multiple operations, only the first
surgery was included for analysis. The final study population
consisted of 35,302 patients. The five most common surgeries in the
cohort were the following: open colectomy (n¼ 2339, 6.6%), carotid
endarterectomy (n¼ 2227, 6.3%), below the knee amputation
(n¼ 2175, 6.2%), total knee arthroplasty (n¼ 1672, 4.7%), and
above the knee amputation (n¼ 1559, 4.4%).
Data collection and measurement
Predictor variables. The magnitude of AKI was determined
according to the percentage increase in creatinine between the
preoperative value (outpatient value within 6 months before
surgery) and the maximum value within 14 days after surgery.
Individuals were stratified by three levels of AKI magnitude
according to the AKIN staging criteria.3 Patients who were initiated
on renal replacement therapy were categorized as ‘failure’, regardless
of the change in their serum creatinine values. AKI duration was
determined by the number of days that subjects met at least the
AKIN Stage 1 definition. A priori, AKI duration was categorized
into three strata: short (p2 days), medium (3–6 days), and long
(X7 days). We chose these thresholds on the basis of our
clinical experience with prerenal and intrinsic AKI. Patients who
required renal replacement therapy were categorized into long
duration, regardless of the number of days that the serum creatinine
remained elevated. For supplementary analyses, we also examined
the relationship between recovery of AKI, duration of AKI,
and long-term survival. Patients who recovered from AKI were
defined as those with AKI who had a discharge serum creatinine
(that is, last creatinine value available before discharge) that was
no more than 0.2mg/dl higher than the preoperative serum
creatinine value.
Outcome variables. The VA National Death Index and the
Beneficiary Identification and Records Locator Subsystem (BIRLS)
database were used to ascertain time until death of patients who
survived hospitalization after noncardiac surgery. Data on survival
time were missing ino7% of patients without AKI and ino4% of
patients with AKI.
Statistical analysis
Comparisons across groups on the basis of baseline characteristics
were performed using analysis of variance for continuous variables
and by w2-tests for categorical variables. Unadjusted survival time
(from the time of hospital discharge) among patients with differing
severities and durations of AKI was examined using the Kaplan–-
Meier method, including median survival times. In subset analyses,
log-rank tests were conducted to test for equality of survivorship by
AKI severity and duration. Moreover, we conducted supplementary
Kaplan–Meier survival analyses using only patients with X7 posto-
perative serum creatinine values. Cox Proportional Hazards
regression analysis was used to evaluate the association between
AKI by severity and duration and long-term survival while adjusting
for potential confounders. Functional forms of each of the variables
in the model were checked and log transformation and construction
of categorical variables from continuous variables were used where
appropriate. Final model selection was carried out using a nonauto-
mated backward selection technique, in which each covariate shown
in Table 1 was removed from an all-inclusive model one at a time.
Likelihood ratio tests were conducted to ensure that omission of
each covariate did not significantly increase the value of the 2 log
likelihood. The proportional hazards assumption was verified by
assessment of Schoenfeld residuals and the log-cumulative hazard
function vs log of time. Goodness of fit was verified by plots of Cox-
Snell, Martingale, and deviance residuals. Data are presented as
hazard ratios with 95% confidence intervals. Analyses were
performed using SAS software (Version 9.1; SAS Institute, Cary,
NC). Kaplan–Meier curves used in publication were graphed
in STATA (Version 10.1, STATA, College Station, TX, USA).
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